Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 7, 2014, Pages 1071-1079

  Lu, Jingwei ^a   Das, Manjusri ^a   Kanji, Suman ^a   Aggarwal, Reeva ^a   Joseph, Matthew ^a   Ray, Alo ^a   Shapiro, Charles L ^a   Pompili, Vincent J ^a   Das, Hiranmoy ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

ATM ATR pathway; Combination therapy; Cytotoxicity; MICA; Ovarian cancer; V 2V 2 T cells

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; CAFFEINE; CURCUMIN; ETOPOSIDE; H 4073; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; HUMAN CELL; LYSIS; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; RECOGNITION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ATM/ATR PATHWAY; COMBINATION THERAPY; CYTOTOXICITY; MICA; OVARIAN CANCER; VΓ2VΔ2 T CELLS;

ANTINEOPLASTIC AGENTS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; OVARIAN NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84899024403     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.003     Document Type: Article

References (50)

1. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
2. Smyth M.J., Hayakawa Y., Takeda K., Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2002, 2:850-861.
3. Gao Y., Yang W., Pan M., Scully E., Girardi M., Augenlicht L.H., Craft J., Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 2003, 198:433-442.
4. Bukowski J.F., Morita C.T., Brenner M.B. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 1999, 11:57-65.
5. D'Souza C.D., Cooper A.M., Frank A.A., Mazzaccaro R.J., Bloom B.R., Orme I.M. An anti-inflammatory role for gamma delta T lymphocytes in acquired immunity to Mycobacterium tuberculosis. J. Immunol. 1997, 158:1217-1221.
6. Caccamo N., Dieli F., Meraviglia S., Guggino G., Salerno A. Gammadelta T cell modulation in anticancer treatment. Curr. Cancer Drug Targets 2010, 10:27-36.
7. Bonneville M., Fournie J.J. Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 2005, 7:503-509.
8. Hayday A.C. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu. Rev. Immunol. 2000, 18:975-1026.
9. Wang L., Kamath A., Das H., Li L., Bukowski J.F. Antibacterial effect of human V gamma 2V delta 2 T cells in vivo. J. Clin. Invest. 2001, 108:1349-1357.
10. Das H., Wang L., Kamath A., Bukowski J.F. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001, 98:1616-1618.
11. Das H., Groh V., Kuijl C., Sugita M., Morita C.T., Spies T., Bukowski J.F. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001, 15:83-93.
12. Cosman D., Mullberg J., Sutherland C.L., Chin W., Armitage R., Fanslow W., Kubin M., Chalupny N.J. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14:123-133.
13. Marincola F.M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 2003, 24:335-342.
14. Kobayashi H., Tanaka Y., Yagi J., Osaka Y., Nakazawa H., Uchiyama T., Minato N., Toma H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 2007, 56:469-476.
15. Bennouna J., Bompas E., Neidhardt E.M., Rolland F., Philip I., Galea C., Salot S., Saiagh S., Audrain M., Rimbert M., Lafaye-de Micheaux S., Tiollier J., Negrier S. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 2008, 57:1599-1609.
16. Hannani D., Ma Y., Yamazaki T., Dechanet-Merville J., Kroemer G., Zitvogel L. Harnessing gammadelta T cells in anticancer immunotherapy. Trends Immunol. 2012, 33:199-206.
17. Lu J., Aggarwal R., Kanji S., Das M., Joseph M., Pompili V., Das H. Human ovarian tumor cells escape gammadelta T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules. PLoS One 2011, 6:e23348.
18. Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem. Sci. 2006, 31:402-410.
19. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
20. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15:2177-2196.
21. Barzilai A., Rotman G., Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 2002, 1:3-25.
22. Li Y., Yang D.Q. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt. Mol. Cancer Ther. 2010, 9:113-125.
23. Ray A., Milum K., Battu A., Wani G., Wani A.A. NER initiation factors, DDB2 and XPC, regulate UV radiation response by recruiting ATR and ATM kinases to DNA damage sites. DNA Repair (Amst) 2013, 12:273-283.
24. D'Andrea A.D., Haseltine W.A. Sequence specific cleavage of DNA by the antitumor antibiotics neocarzinostatin and bleomycin. Proc. Natl. Acad. Sci. U. S. A. 1978, 75:3608-3612.
25. Tanaka T., Halicka H.D., Traganos F., Seiter K., Darzynkiewicz Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 2007, 6:371-376.
26. Yap T.A., Carden C.P., Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer 2009, 9:167-181.
27. Ozols R.F. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs 1999, 58(Suppl. 3):43-49.
28. Hoskins P.J., Swenerton K.D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 1994, 12:60-63.
29. Selvendiran K., Tong L., Bratasz A., Kuppusamy M.L., Ahmed S., Ravi Y., Trigg N.J., Rivera B.K., Kalai T., Hideg K., Kuppusamy P. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol. Cancer Ther. 2010, 9:1169-1179.
30. Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B., Walker C.L. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4153-4158.
31. Lake R.A., Robinson B.W. Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 2005, 5:397-405.
32. Feldman E.J., Brandwein J., Stone R., Kalaycio M., Moore J., O'Connor J., Wedel N., Roboz G.J., Miller C., Chopra R., Jurcic J.C., Brown R., Ehmann W.C., Schulman P., Frankel S.R., De Angelo D., Scheinberg D. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 2005, 23:4110-4116.
33. Linck D., Lentini G., Tiemann M., Fauser A.A., Parwaresch R., Basara N. Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma. Leuk. Lymphoma 2005, 46:285-288.
34. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
35. Capietto A.H., Martinet L., Fournie J.J. How tumors might withstand gammadelta T-cell attack. Cell. Mol. Life Sci. 2011, 68:2433-2442.
36. Groh V., Steinle A., Bauer S., Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998, 279:1737-1740.
37. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
38. Yamamoto K., Fujiyama Y., Andoh A., Bamba T., Okabe H. Oxidative stress increases MICA and MICB gene expression in the human colon carcinoma cell line (CaCo-2). Biochim. Biophys. Acta 2001, 1526:10-12.
39. Dituri F., Mazzocca A., Giannelli G., Antonaci S. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin. Dev. Immunol. 2011, 2011:947858.
40. McAuliffe P.F., Meric-Bernstam F., Mills G.B., Gonzalez-Angulo A.M. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin. Breast Cancer 2010, 10(Suppl. 3):S59-S65.
41. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8:187-198.
42. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
43. Faghiri Z., Bazan N.G. PI3K/Akt and mTOR/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis. Exp. Eye Res. 2010, 90:718-725.
44. Guo Z., Kozlov S., Lavin M.F., Person M.D., Paull T.T. ATM activation by oxidative stress. Science 2010, 330:517-521.
45. Ditch S., Paull T.T. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem. Sci. 2012, 37:15-22.
46. Shackelford R.E., Kaufmann W.K., Paules R.S. Oxidative stress and cell cycle checkpoint function. Free Radic. Biol. Med. 2000, 28:1387-1404.
47. Mistry A.R., O'Callaghan C.A. Regulation of ligands for the activating receptor NKG2D. Immunology 2007, 121:439-447.
48. Lin X., Yan J., Tang D. ERK kinases modulate the activation of PI3 kinase related kinases (PIKKs) in DNA damage response. Histol. Histopathol. 2013, 28:1547-1554.
49. Roos W.P., Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 2006, 12:440-450.
50. Ambrose M., Gatti R.A. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood 2013, 121:4036-4045.